Hybrigenics SA operates as a biopharmaceutical company which engages in the research and development of targets and therapies for the treatment of proliferative diseases. It develops inecalcitol for the treatment of prostate cancer, acute and chronic lymphocytic leukemia, and acute and chronic myeloid leukemia. The company was founded by Arthur Donny Strosberg on December 29, 1997 and is headquartered in Paris, France.